{
"id":"mk19_b_hm_q069",
"number":69,
"bookId":"hm",
"correctAnswer":"A",
"title":"Question 69",
"stimulus":[
{
"type":"p",
"hlId":"142459",
"children":[
"A 23-year-old woman is evaluated during a routine follow-up appointment. She has β-thalassemia major for which she has received approximately 15 transfusions since childhood; she becomes symptomatic when the ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"hemoglobin"
]
},
" level is less than 7 g/dL (70 g/L). Medical history is otherwise noncontributory. Her only medication is folic acid."
]
},
{
"type":"p",
"hlId":"a2ad52",
"children":[
"On physical examination, vital signs are normal. Hepatosplenomegaly is present."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"41a9a7",
"class":"cell text l",
"children":[
"7.9 g/dL (79 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"7450c0",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Iron studies, Iron, serum",
"children":[
"Iron studies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a5c037",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Iron studies, Ferritin, serum",
"children":[
"Ferritin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5ef354",
"class":"cell text l",
"children":[
"3228 ng/mL (3228 μg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"1f3a27",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Iron studies, Iron, serum",
"children":[
"Iron"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"47c16f",
"class":"cell text l",
"children":[
"212 μg/dL (38 μmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"88bfbc",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Iron studies, Transferrin saturation",
"children":[
"Transferrin saturation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"84d1af",
"class":"cell text l",
"children":[
"56%"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Oral iron chelation"
}
},
{
"letter":"B",
"text":{
"__html":"Phlebotomy"
}
},
{
"letter":"C",
"text":{
"__html":"Plasmapheresis"
}
},
{
"letter":"D",
"text":{
"__html":"Transfusion at hemoglobin threshold of 6 g/dL (60 g/L)"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"921c76",
"children":[
"In patients requiring chronic blood transfusions, chelation therapy should be instituted when laboratory evidence indicates iron overload but before signs of end-organ injury to the liver or heart appear."
]
},
{
"type":"keypoint",
"hlId":"8e69e4",
"children":[
"Patients requiring chronic blood transfusions should be monitored for evidence of iron overload with serial ferritin level measurements, and MRI should be considered to evaluate iron deposition in the liver or heart."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"80009a",
"children":[
"Oral iron chelation is the most appropriate treatment for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). She has secondary iron overload and requires intervention to decrease the iron burden to reduce the risk for organ damage, particularly liver and cardiac toxicity. Iron overload is a significant complication for transfusion-dependent patients with β-thalassemia major. Excess iron accumulates from repeat erythrocyte transfusions and from increased gastrointestinal absorption. Overt iron overload can be seen after transfusion of 15 to 20 units of blood. Patients requiring chronic transfusions are therefore at risk for developing secondary iron overload. Individuals should be monitored for evidence of iron overload with serial ferritin level measurements, and MRI should be considered to evaluate iron deposition in the liver or heart. Chelation therapy should begin before end-organ injury to the liver or heart is evident. Chelation has been demonstrated to reduce organ iron levels and prolong survival in patients with thalassemia. It is often initiated when the serum ferritin level exceeds 1000 ng/mL (1000 μg/L), after approximately 15 to 20 units of blood have been transfused, or with evidence of organ deposition (>3 mg of iron per gram dry weight in the liver or cardiac T2* <20 milliseconds on MRI)."
]
},
{
"type":"p",
"hlId":"929040",
"children":[
"Regularly scheduled phlebotomy is the accepted care in managing patients with primary hemochromatosis and iron overload but is contraindicated in patients who are transfusion dependent because of existing anemia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
")."
]
},
{
"type":"p",
"hlId":"9c8647",
"children":[
"Apheresis and plasmapheresis are not effective means for reducing iron levels (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Much of the excess iron is stored in extravascular sites and is not accessible for removal by pheresis."
]
},
{
"type":"p",
"hlId":"d32122",
"children":[
"Evidence-based care of patients with β-thalassemia major is regular transfusion, with a therapeutic target of 9.5 to 10.5 g/dL (95-105 g/L). Restricting transfusion would not be recommended nor would it address the patient's iron overload (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
")."
]
}
],
"relatedSection":"mk19_b_hm_s5_2",
"objective":{
"__html":"Treat secondary iron overload with iron chelation therapy."
},
"references":[
[
"Coates TD. Iron overload in transfusion-dependent patients. Hematology Am Soc Hematol Educ Program. 2019;2019:337-344. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31808901",
"target":"_blank"
},
"children":[
"PMID: 31808901"
]
},
" doi:10.1182/hematology.2019000036"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":87,
"B":4,
"C":6,
"D":3,
"E":0
},
"hlIds":[
"142459",
"a2ad52",
"a462a3",
"f9867c",
"41a9a7",
"7450c0",
"d41d8c",
"a5c037",
"5ef354",
"1f3a27",
"47c16f",
"88bfbc",
"84d1af",
"1054f1",
"921c76",
"8e69e4",
"80009a",
"929040",
"9c8647",
"d32122"
]
}